Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...
GlobalData on MSN2d
Gilead and MSD to advance once-weekly HIV treatment to Phase IIIThe companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Maharashtra launches a groundbreaking 28-day TB treatment for HIV patients aiming to reduce mortality and improve healthcare ...
GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
A new study published in the Journal of Clinical Tuberculosis and Other Mycobacterial Diseases showed that two ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV ...
The antiretroviral drug has been hailed as a potential ... generics companies will be able to make a lower-cost version of the HIV prevention regimen, subject to regulatory approvals, in 120 ...
Analysis of TORO (T-20 vs Optimized Regimen Only Study) Data For each subgroup, change from baseline in plasma HIV RNA, CD4 count, drug acquisition costs and acquisition costs per unit ...
Anemia prevalence was high in adult patients with HIV infection on HAART, with female sex, older age, and nonsuppressed viral load status identified as significant predictors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback